Norvir (ritonavir)

Company
Abbott Laboratories

Approval Status
Approved June 1999

Treatment for
Immunology/Infectious Diseases

Possible similar drugs
Norvir

Areas
Immune System

Norvir soft-gelatin capsules (new formulation) have been approved for the treatment of HIV infection. Norvir is a protease inhibitor indicated in combination with other antiretroviral medications for the treatment of HIV infection. The soft-gel capsules required refrigerated storage until dispensed to patients. Norvir is approved for twice-daily use and should be taken with food, if possible.

Taken in combination with other antiretroviral medications for the treatment of HIV infection, this indication for Norvir is based on the results from a study in patients with advanced HIV disease that showed a reduction in both mortality and AIDS-defining clinical events. Norvir has also been approved by the FDA for use in children between the ages of 2 and 16 based on safety and pharmacokinetic data.

Common adverse reactions include fatigue, vomiting, diarrhea, loss of appetite, abdominal pain, taste disturbance, tingling sensation or numbness in the hands, feet, or around the lips, headache and dizziness.

Norvir_540 Drug Information

The Norvir_540 drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top